 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

MALVERN, Pa., Sept. 18, 2023 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel...

Galera Schedules Type A Meeting with FDA to Discuss Next Steps for Avasopasem

MALVERN, Pa., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel...

Galera to Participate in the H.C. Wainwright 25th Annual Global Investment Conference

In a report released yesterday, Yigal Nochomovitz from Citi maintained a Hold rating on Galera Therapeutics (GRTX Research Report), with a price ... In a report released yesterday, Yigal Nochomovitz from Citi maintained a Hold rating on Galera Therapeutics (GRTX &#8211...

Citi Sticks to Its Hold Rating for Galera Therapeutics (GRTX)

HC Wainwright downgraded shares of Galera Therapeutics (NASDAQ:GRTX  Free Report) from a buy rating to a neutral rating in a research report sent to investors on Wednesday morning, MarketBeat.com reports. HC Wainwright also issued estimates for Galera Therapeutics Q3 2023 earnings at...

Galera Therapeutics (NASDAQ:GRTX) Rating Lowered to Neutral at HC Wainwright

Galera Therapeutics, Inc. (NASDAQ:GRTX Free Report) Investment analysts at HC Wainwright reduced their Q3 2023 EPS estimates for shares of Galera Therapeutics in a research report issued to clients and investors on Wednesday, August 16th. HC Wainwright analyst B. Pachaiyappan now forecasts that the ...

Q3 2023 EPS Estimates for Galera Therapeutics, Inc. (NASDAQ:GRTX) Decreased by HC Wainwright

Galera Therapeutics, Inc. (NASDAQ:GRTX  Free Report)  Investment analysts at HC Wainwright reduced their Q3 2023 EPS estimates for shares of Galera Therapeutics in a research report issued to clients and investors on Wednesday, August 16th. HC Wainwright analyst B. Pachaiyappan now ...

HC Wainwright cut shares of Galera Therapeutics (NASDAQ:GRTX Free Report) from a buy rating to a neutral rating in a research note released on Wednesday, MarketBeat Ratings reports. HC Wainwright also issued estimates for Galera Therapeutics Q3 2023 earnings at ($0.41) EPS, Q4 2023 earnings at ($0....

Galera Therapeutics (NASDAQ:GRTX) Downgraded by HC Wainwright

Citigroup downgraded shares of Galera Therapeutics (NASDAQ:GRTX Free Report) from a buy rating to a neutral rating in a report released on Monday morning, FlyOnTheWall reports. A number of other equities research analysts also recently issued reports on GRTX. Bank of America downgraded shares of ...

Galera Therapeutics (NASDAQ:GRTX) Stock Rating Lowered by Citigroup

Galera Therapeutics (GRTX Research Report) received a Hold rating and a $0.30 price target from H.C. Wainwright analyst Ram Selvaraju today. The ... Galera Therapeutics (GRTX  Research Report) received a Hold rating and a $0.30 price target from H.C. Wainwright analyst...

H.C. Wainwright downgrades Galera Therapeutics (GRTX) to a Hold

Thinking about buying stock in Rivian Automotive, Joby Aviation, Research Solutions, Galera Therapeutics, or Adial Pharmaceuticals? Thinking about buying stock in Rivian Automotive, Joby Aviation, Research Solutions, Galera Therapeutics, or Adial Pharmaceuticals? PR Newswire NEW YORK, Aug. 15, 2023...

Thinking about buying stock in Rivian Automotive, Joby Aviation, Research Solutions, Galera Therapeutics, or Adial Pharmaceuticals?

Galera Therapeutics, Inc. is a clinical stage biotechnology company, which engages in developing and commercializing a pipeline of novel, proprietary therapeutics for cancer. It is also involved in the prevention of radiation-induced toxicity, including mucositis and the treatment of fibrosis, and cancer. The company was founded by Robert A. Beardsley, Randy W. Weiss, and Dennis P. Riley in 2009 and is headquartered in Malvern, PA.

Watchers	5,370
52-Wk Low	$0.1724
52-Wk High	$3.59

Market Cap	$7.78M
Volume (M)	2.98M
52-Wk High	$3.59
52-Wk Low	$0.1724

GRTX Galera Therapeutics Inc

About

Feed

News

Sentiment

Fundamentals